JP2018504919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504919A5 JP2018504919A5 JP2017548375A JP2017548375A JP2018504919A5 JP 2018504919 A5 JP2018504919 A5 JP 2018504919A5 JP 2017548375 A JP2017548375 A JP 2017548375A JP 2017548375 A JP2017548375 A JP 2017548375A JP 2018504919 A5 JP2018504919 A5 JP 2018504919A5
- Authority
- JP
- Japan
- Prior art keywords
- bacterium
- gene
- bacterium according
- arginine
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims 31
- 239000004475 Arginine Substances 0.000 claims 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 108010032178 Amino-acid N-acetyltransferase Proteins 0.000 claims 7
- 102000007610 Amino-acid N-acetyltransferase Human genes 0.000 claims 6
- 206010021143 Hypoxia Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000007954 hypoxia Effects 0.000 claims 5
- 206010020575 Hyperammonaemia Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 101150118463 argG gene Proteins 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000019932 Aciduria Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010062695 Arginase deficiency Diseases 0.000 claims 1
- 208000034318 Argininemia Diseases 0.000 claims 1
- 206010058298 Argininosuccinate synthetase deficiency Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010058297 Carbamoyl phosphate synthetase deficiency Diseases 0.000 claims 1
- 208000033910 Carbamoyl-phosphate synthetase 1 deficiency Diseases 0.000 claims 1
- 201000011297 Citrullinemia Diseases 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 claims 1
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 claims 1
- 206010021113 Hypothermia Diseases 0.000 claims 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 241000194036 Lactococcus Species 0.000 claims 1
- 108700043217 N-acetyl glutamate synthetase deficiency Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 claims 1
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 claims 1
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 claims 1
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010038664 Respiratory alkalosis Diseases 0.000 claims 1
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 101150089004 argR gene Proteins 0.000 claims 1
- KDZOASGQNOPSCU-UHFFFAOYSA-N argininosuccinate Chemical compound OC(=O)C(N)CCCN=C(N)NC(C(O)=O)CC(O)=O KDZOASGQNOPSCU-UHFFFAOYSA-N 0.000 claims 1
- 210000003578 bacterial chromosome Anatomy 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000001851 biosynthetic effect Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 208000022843 carbamoyl phosphate synthetase I deficiency disease Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 101150073654 dapB gene Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 201000011286 hyperargininemia Diseases 0.000 claims 1
- 230000002631 hypothermal effect Effects 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 101150072314 thyA gene Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000004143 urea cycle Effects 0.000 claims 1
- 208000030954 urea cycle disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087854P | 2014-12-05 | 2014-12-05 | |
| US62/087,854 | 2014-12-05 | ||
| US201562103513P | 2015-01-14 | 2015-01-14 | |
| US62/103,513 | 2015-01-14 | ||
| US201562150508P | 2015-04-21 | 2015-04-21 | |
| US62/150,508 | 2015-04-21 | ||
| US201562173710P | 2015-06-10 | 2015-06-10 | |
| US201562173706P | 2015-06-10 | 2015-06-10 | |
| US62/173,710 | 2015-06-10 | ||
| US62/173,706 | 2015-06-10 | ||
| US201562183935P | 2015-06-24 | 2015-06-24 | |
| US62/183,935 | 2015-06-24 | ||
| US201562184811P | 2015-06-25 | 2015-06-25 | |
| US62/184,811 | 2015-06-25 | ||
| US201562256039P | 2015-11-16 | 2015-11-16 | |
| US201562256041P | 2015-11-16 | 2015-11-16 | |
| US62/256,041 | 2015-11-16 | ||
| US62/256,039 | 2015-11-16 | ||
| US201562263329P | 2015-12-04 | 2015-12-04 | |
| US62/263,329 | 2015-12-04 | ||
| PCT/US2015/064140 WO2016090343A1 (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504919A JP2018504919A (ja) | 2018-02-22 |
| JP2018504919A5 true JP2018504919A5 (OSRAM) | 2019-01-24 |
| JP6768689B2 JP6768689B2 (ja) | 2020-10-14 |
Family
ID=55022714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548375A Expired - Fee Related JP6768689B2 (ja) | 2014-12-05 | 2015-12-04 | 高アンモニア血症に関連する病気を処置するために操作された細菌 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9487764B2 (OSRAM) |
| JP (1) | JP6768689B2 (OSRAM) |
| KR (1) | KR102493174B1 (OSRAM) |
| AU (1) | AU2015357549B2 (OSRAM) |
| BR (1) | BR112017011923A2 (OSRAM) |
| CA (1) | CA2969724A1 (OSRAM) |
| IL (2) | IL252627B (OSRAM) |
| MX (2) | MX383245B (OSRAM) |
| SG (2) | SG10202010444UA (OSRAM) |
| WO (1) | WO2016090343A1 (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US9487764B2 (en) * | 2014-12-05 | 2016-11-08 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| EP3294760B1 (en) | 2015-05-13 | 2021-03-24 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| WO2016210384A2 (en) * | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| US11766461B2 (en) | 2016-04-20 | 2023-09-26 | The Board of Trustees of the Stanford Junior | Compositions and methods for nucleic acid expression and protein secretion in Bacteroides |
| EP3554518A4 (en) | 2016-12-15 | 2020-07-29 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS FOR MODULATING THE GROWTH OF A GENETICALLY MODIFIED INTESTINAL BACTERIAL CELL |
| BR112019013863A2 (pt) | 2017-01-06 | 2020-03-03 | Synlogic Operating Company, Inc. | Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais |
| WO2018195097A1 (en) * | 2017-04-17 | 2018-10-25 | The Regents Of The University Of California | Engineered commensal bacteria and methods of use |
| JP7358245B2 (ja) | 2017-06-21 | 2023-10-10 | シンロジック オペレーティング カンパニー インコーポレイテッド | 障害の処置のための細菌 |
| WO2019006246A1 (en) * | 2017-06-30 | 2019-01-03 | The Rockefeller University | N-ACYL AMIDES DERIVED FROM THE HUMAN MICROBIOTE FOR THE TREATMENT OF A HUMAN DISEASE |
| JP2020527025A (ja) * | 2017-07-12 | 2020-09-03 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| US12090168B2 (en) | 2017-11-03 | 2024-09-17 | Dsm Nutritional Products, Llc | Glucose glycans for treating urea cycle disorders |
| JP7460531B2 (ja) * | 2017-12-05 | 2024-04-02 | バイオピーエルエックス，インコーポレイティド | 微生物感染を防ぐための方法および組成物 |
| WO2019118984A2 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| EP3801502A4 (en) | 2018-06-02 | 2022-04-20 | Synlogic Operating Company, Inc. | MODIFIED BACTERIA TO TREAT LIVER DISEASE |
| CN113056488B (zh) | 2018-08-21 | 2023-10-24 | Dsm营养产品有限责任公司 | 寡糖组合物及其用于降低氨水平的使用方法 |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| SG11202104207TA (en) | 2018-11-08 | 2021-05-28 | Kaleido Biosciences Inc | Oligosaccharide compositions and methods of use thereof |
| JP2022530503A (ja) | 2019-04-29 | 2022-06-29 | シンロジック オペレーティング カンパニー インコーポレイテッド | 遺伝子操作された微生物 |
| WO2020237246A1 (en) * | 2019-05-23 | 2020-11-26 | University Of Maryland, Baltimore | Live attenuated non-transmissible vaccines |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| EP4067476B1 (en) | 2019-11-29 | 2025-08-27 | Jinis Co., Ltd. | Strain having ability to lower blood ammonia levels and composition comprising same for neuronal protection |
| CN112924607A (zh) * | 2019-12-05 | 2021-06-08 | 湖北远大生物技术有限公司 | 一种同时检测酶促反应液中α-酮戊二酸和L-谷氨酸的方法 |
| JP2023518184A (ja) | 2020-03-20 | 2023-04-28 | シンロジック オペレーティング カンパニー インコーポレイテッド | 高フェニルアラニン血症を軽減するように遺伝子改変された微生物 |
| CA3200887A1 (en) | 2020-12-02 | 2022-06-09 | Michael James | Engineered microorganisms |
| CA3238788A1 (en) | 2021-11-22 | 2023-05-25 | Eric Michael Schott | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
| CN115960807A (zh) * | 2022-11-29 | 2023-04-14 | 深圳先进技术研究院 | 一种厌氧高产l-精氨酸工程菌及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| WO2000032748A1 (en) | 1998-12-02 | 2000-06-08 | Trustees Of Boston University | Gene networks for control of gene expression |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| JP4682454B2 (ja) * | 2000-06-28 | 2011-05-11 | 味の素株式会社 | 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法 |
| DE10101793A1 (de) * | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| EP1801206B1 (en) * | 2004-09-28 | 2010-03-24 | Kyowa Hakko Bio Co., Ltd. | Method for producing l-arginine, l-ornithine or l-citrulline |
| US9487764B2 (en) * | 2014-12-05 | 2016-11-08 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
-
2015
- 2015-12-04 US US14/960,333 patent/US9487764B2/en active Active
- 2015-12-04 BR BR112017011923A patent/BR112017011923A2/pt not_active Application Discontinuation
- 2015-12-04 SG SG10202010444UA patent/SG10202010444UA/en unknown
- 2015-12-04 MX MX2017007148A patent/MX383245B/es unknown
- 2015-12-04 WO PCT/US2015/064140 patent/WO2016090343A1/en not_active Ceased
- 2015-12-04 KR KR1020177018338A patent/KR102493174B1/ko active Active
- 2015-12-04 AU AU2015357549A patent/AU2015357549B2/en not_active Ceased
- 2015-12-04 CA CA2969724A patent/CA2969724A1/en not_active Abandoned
- 2015-12-04 JP JP2017548375A patent/JP6768689B2/ja not_active Expired - Fee Related
- 2015-12-04 SG SG11201704543XA patent/SG11201704543XA/en unknown
-
2017
- 2017-06-01 IL IL252627A patent/IL252627B/en active IP Right Grant
- 2017-06-05 MX MX2021006581A patent/MX2021006581A/es unknown
-
2020
- 2020-10-19 IL IL278150A patent/IL278150A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504919A5 (OSRAM) | ||
| JP2018515106A5 (OSRAM) | ||
| Wegmann et al. | Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp. cremoris MG1363 | |
| Siezen et al. | Complete sequences of four plasmids of Lactococcus lactis subsp. cremoris SK11 reveal extensive adaptation to the dairy environment | |
| Van Pijkeren et al. | High efficiency recombineering in lactic acid bacteria | |
| AU2013327059B2 (en) | Immunomodulatory minicells and methods of use | |
| CN102046791B (zh) | 表达载体 | |
| ES2266515T3 (es) | Cepa de lactococcus con autocontencion. | |
| US8535939B2 (en) | Transfection vector | |
| BRPI0418805B1 (pt) | construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos | |
| CN111315868B (zh) | 靶向肿瘤和治疗癌症的细菌 | |
| van Kranenburg et al. | Nucleotide sequence analysis of the lactococcal EPS plasmid pNZ4000 | |
| WO2004046346A2 (en) | Self-containing lactobacillus strain | |
| Chen et al. | Characterization of pMC11, a plasmid with dual origins of replication isolated from Lactobacillus casei MCJ and construction of shuttle vectors with each replicon | |
| JP2018521674A5 (OSRAM) | ||
| EP3541942A1 (en) | Conjugative vectors selectable by fructooligosaccharides | |
| CN114761563A (zh) | 诱导型质粒自毁辅助重组 | |
| US12491236B2 (en) | Genetically engineered live bacteria and methods of constructing the same | |
| Kwon et al. | Genetically engineered Salmonella typhimurium for targeted cancer therapy | |
| Guo et al. | Developing the Limosilactobacillus reuteri chassis through an endogenous programmable endonuclease-based genome editing tool | |
| Fukiya et al. | Technological advances in bifidobacterial molecular genetics: application to functional genomics and medical treatments | |
| CN102586324A (zh) | 一种用于基因治疗的细胞的构建方法及制得的细胞 | |
| 김혜준 | Development of the Cas9-gRNA ribonucleoprotein-meditated editing for inactivation of hemolysin gene in Lactiplantibacillus plantarum | |
| CN120464662A (zh) | 一种表达环二腺苷酸的乳酸乳球菌重组菌及其应用 | |
| JP2015519061A5 (OSRAM) |